Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease
European Archives of Oto-Rhino-Laryngology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 25, 2025
Язык: Английский
State of the Art in the Diagnosis and Assessment of Oral Malignant and Potentially Malignant Disorders: Present Insights and Future Outlook—An Overview
Bioengineering,
Год журнала:
2024,
Номер
11(3), С. 228 - 228
Опубликована: Фев. 28, 2024
Oral
Potentially
Malignant
Disorder
(OPMD)
is
a
significant
concern
for
clinicians
due
to
the
risk
of
malignant
transformation.
Squamous
Cell
Carcinoma
(OSCC)
common
type
cancer
with
low
survival
rate,
causing
over
200,000
new
cases
globally
each
year.
Despite
advancements
in
diagnosis
and
treatment,
five-year
rate
OSCC
patients
remains
under
50%.
Early
can
greatly
improve
chances
survival.
Therefore,
understanding
development
transformation
developing
diagnostic
methods
crucial.
The
field
oral
medicine
has
been
advanced
by
technological
molecular
innovations,
leading
integration
medical
technologies
into
dental
practice.
This
study
aims
outline
potential
role
non-invasive
imaging
techniques
signatures
early
detection
Disorders.
Язык: Английский
Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
Oral Oncology,
Год журнала:
2025,
Номер
162, С. 107208 - 107208
Опубликована: Фев. 2, 2025
Язык: Английский
Diagnostic Accuracy of Circulating Tumor HPV DNA Testing in Patients With a Lateral Neck Mass
JAMA Otolaryngology–Head & Neck Surgery,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 19, 2024
The
most
frequent
presenting
symptom
for
patients
with
human
papillomavirus
(HPV)-associated
oropharyngeal
squamous
cell
carcinoma
(OPSCC)
is
a
lateral
neck
mass.
Circulating
tumor
tissue-modified
viral
(TTMV)-HPV
DNA
unique
biomarker
produced
by
the
fragmentation
of
HPV
during
degradation
HPV-associated
tumors,
and
its
detection
quantitation
are
currently
being
used
as
an
adjunct
to
imaging
in
monitoring
disease
recurrence
may
have
utility
diagnosis.
Язык: Английский
Human papillomavirus circulating tumor DNA assays as a mechanism for head and neck cancer equity in rural regions of the United States
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Май 8, 2024
The
rates
of
human
papillomavirus-positive
oropharyngeal
cancer
(HPV-OPC)
are
rising
worldwide
and
in
the
United
States,
particularly
rural
regions
including
Appalachia.
Rural
areas
face
unique
health
challenges
resulting
higher
incidence
mortality
rates,
this
includes
HPV-OPC.
recent
advent
highly
sensitive
liquid
biopsies
for
non-invasive
detection
HPV-OPC
recurrence
(circulating
tumor
HPV
DNA,
ctDNA)
has
been
swiftly
adopted
as
part
surveillance
paradigms.
Though
knowledge
gaps
persist
regarding
its
use
clinical
trials
ongoing,
ease
collection
cost-effectiveness
ctDNA
make
it
more
accessible
survivors
than
usual
methods
frequent
exams
imaging.
Herein,
we
discuss
how
implementing
assays
States
provide
one
poignant
example
can
improve
care
equity.
Язык: Английский
Imaging Modalities for Head and Neck Cancer
Surgical Oncology Clinics of North America,
Год журнала:
2024,
Номер
33(4), С. 617 - 649
Опубликована: Май 11, 2024
Язык: Английский
Identification and Surveillance of Unusual Primary Site Using Human Papillomavirus‐Specific Cell‐Free Tumor DNA
Otolaryngology,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 17, 2024
The
increasing
incidence
of
head
and
neck
squamous
cell
carcinoma
(HNSCC)
is
associated
with
the
rising
prevalence
human
papillomavirus
(HPV)-associated
disease.1
HPV-associated
HNSCC
represents
a
distinct
clinical
entity
favorable
prognosis
compared
to
non-HPV-associated
HNSCC.1
Current
guidelines
recommend
imaging
within
6
months
after
treatment
office-based
physical
exams
from
that
point
at
specified
intervals.
However,
surveillance
in
this
population
can
be
demanding
as
providers
balance
patient
anxieties.
An
intermediate
mechanism
desired.
There
has
been
utility
circulating
cell-free
tumor
DNA
(ctDNA)
diagnostic
tool
for
HNSCC.2
A
commercially
available
blood
test
known
tissue-modified
viral
(TTMV)-HPV
(NavDx;
Naveris
Inc)
testing
shown
promise
regard.2
In
report,
we
highlight
NavDx
an
unusual
case
unknown
origin
emergence
unique
primary
site.
Such
advancements
present
promising
avenue
early
detection
HNSCC,
revolutionizing
way
disease
managed.3
74-year-old
female
never-smoker
presented
3-week
history
nontender
left
mass.
Review
systems
was
otherwise
negative.
Physical
exam
nasal
endoscopy
did
not
reveal
any
abnormalities.
Computed
tomography
(CT)
soft
tissue
showed
solitary
cystic
level
IIA
node;
upper
aerodigestive
tract
normal.
She
referred
otolaryngology
fine
needle
aspiration
(FNA)
which
(SCC).
Primary
site
remained
following
pretreatment
whole
body
positron
emission
(PET)-CT
scan.
After
review
multidisciplinary
board,
she
underwent
selective
dissection
(levels
II-IV)
well
palatine
lingual
tonsillar
resection.
Pathology
revealed
p16-positive
1.4
cm
I
node
without
extracapsular
extension;
confirmatory
HPV
in-situ
hybridization
positive.
additional
33
nodes,
tonsil
specimens,
were
negative
carcinoma.
Patient
then
NavDx.
score
5
(positive)
5-months
postoperatively
3
(indeterminant)
8-months
postoperatively.
Then,
15-months
postoperatively,
increased
61,
16-months
it
571.
(Figure
1).
This
prompted
further
evaluation
determine
Repeat
CT
subtle
thickening
along
anterior
superior
cavity
cortical
thinning,
erosion
bone,
mucosal
toward
cribriform
plate
2).
On
endoscopy,
inferior
turbinate
found
hyperplastic
overt
evidence
surface
Biopsy
SCC,
confirming
cavity.
subsequently
endoscopic
more
extensive
than
suggested
by
involved
septal
mucosa
extending
plate,
floor,
lateral
wall,
ethmoid
Surgical
removal
total
septectomy,
degloving,
medial
maxillectomy
via
Denker's
approach,
bilateral
sinus
surgery,
modified
Lothrop
frontal
drill
out,
repair
defect
using
flap.
recovered
6-weeks
adjuvant
radiation
therapy
decline
20.
Approximately
2-months
radiation,
had
enlargement
IB
(9-12
mm),
V,
multiple
right-sided
nodes.
decreased
11,
however,
positive
score.
Posttreatment
PET
scan
hypermetabolic
levels
IB,
right
IV
nodes
concerning
metastasis.
FNA
atypical
cells
suspicious
malignancy.
1
out
59
removed
IB.
report
describes
novel
application
TTMV-HPV
monitoring
ctDNA
context
HPV-related
sinonasal
SCC.
oropharynx
interest
majority
primaries
neck,4
however
nonoropharyngeal
may
well.
first
documented
management
neck,
including
previous
used
monitor
anal
SCC.5
growing
utilizing
potential
pending
research.
Therefore,
future
studies
should
establish
efficacy
non-oropharyngeal
SCC
because
intervention
translates
lower
resource
utilization
outcomes.
Russell
A.
Whitehead,
drafted,
edited,
approved
final
manuscript
takes
full
responsibility
its
content;
Peter
Papagiannopoulos,
Nikhil
Joshi,
Mihir
K.
Bhayani,
content.
None.
Язык: Английский
Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma
Oral Oncology,
Год журнала:
2024,
Номер
156, С. 106894 - 106894
Опубликована: Июнь 22, 2024
Язык: Английский
Circulating tumor DNA in head and neck squamous cell carcinoma—current status and future prospects
Academia oncology.,
Год журнала:
2024,
Номер
1(2)
Опубликована: Дек. 19, 2024
Squamous
cell
carcinoma
(SCC)
is
the
most
common
malignancy
of
head
and
neck.
Stagnating
survival
rates
in
recent
decades,
despite
advances
treatment
paradigms,
surveillance
technologies,
multidisciplinary
care,
leave
clinicians
with
a
need
for
better
options
screening,
risk-stratifying,
monitoring
patients.
A
growing
proportion
patients
HPV-associated
SCC
have
improved
outcomes
but
continue
to
heterogenous
response
treatment.
Advances
platforms
assays
measuring
circulating
tumor
DNA
offer
an
opportunity
monitor
disease
status
at
molecular
level
both
virally
mediated
traditional
risk-factor-driven
This
overview
will
discuss
experimental,
clinically
used,
commercially
available
liquid
biopsy
their
applications
neck
malignancies.
Язык: Английский